it  (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of it, presumably due to negative trial results (though no results were reported). it is an oxazolidinone antibiotic agent with bactericidal activity against common gram-positive bacteria. 
